Vagus-stimulating breathing technique before and during in- and outpatient treatment for patients with psychosomatic disorders

Organizational Data

DRKS-ID:
DRKS00032629
Recruitment Status:
Recruiting ongoing
Date of registration in DRKS:
2023-10-27
Last update in DRKS:
2023-12-08
Registration type:
Prospective

Acronym/abbreviation of the study

VAST

URL of the study

No Entry

Brief summary in lay language

The positive effects of mind-body practices (e.g. yoga, meditation, tai chi) have long been well known. Thereby, slow breathing in a certain beat is an essential part of these practices. A systematic review of a total of 58 clinical studies concluded that relevant improvements in emotional and physical health and performance can be achieved through breathing-based biofeedback (Lehrer et al. 2020, DOI: 10.1007/s10484-020-09466-z). In all of these studies, slow paced breathing at the so-called resonance frequency was used. This resonance breathing involves breathing at a rate of 6 breaths per minute in a specific pattern that increases the activity of the vagus nerve (called vagus nerve stimulation). The vagus nerve is one of the largest and most widely branched nerves of the autonomic nervous system, originating directly in the brain (10th cranial nerve) and connecting it to all organs in the body. It also has connections with the immune system that can reduce inflammation in the body. Thus, regular, consistent use of this type of stimulation can so significantly improve emotional and physical health. In the strictly randomized controlled BEAT-COVID study, we have already been able to lower the body-wide inflammatory response in COVID-19 patients admitted to the infection ward in the hospital through resonance breathing (Balint et al. 2022, DOI: 10.3389/fimmu.2022.928979, DRKS00023971). Another of our clinical studies shows that patients with a wide range of psychosomatic disorders often show slightly elevated levels of inflammation as well as various difficulties in the area of emotion regulation. The aim of the VAST study is to improve low-threshold inflammation and the ability to regulate emotions through the daily application of a vagus-stimulating breathing technique (resonance breathing) in patients of the University Clinic for Psychosomatic Medicine and Psychotherapy in Ulm. The study participation lasts a total of four months with a total of four on-site examination appointments. Participants will receive a total of €80 for full participation (€20 per examination appointment).

Brief summary in scientific language

Scientific studies show positive effects of mind-body practices, especially resonance breathing, also on the health of patients with psychosomatic disorders. These practices, which include yoga, meditation, and tai chi, have long been shown to have positive effects on the body and mind. A significant feature of these techniques is slow paced breathing (called resonance breathing). A meta-analysis of 58 studies, as described in Lehrer et al. (2020, DOI: 10.1007/s10484-020-09466-z), has shown significant improvements in emotional and physical health and performance, with statistically significant mean effect sizes. In particular, "HRV biofeedback" has been focused on. Interestingly, most of these studies use simple resonance breathing with a general breathing rate of 6 breaths per minute, rather than determining the individual resonance rate more precisely. This greatly simplifies the application in practice. A significant finding from a clustered randomized controlled trial (RCT) (Caldwell & Steffen, 2018, DOI: 10.1016/j.ijpsycho.2018.01.001) is that a slow abdominal breathing technique with 6 breaths per minute produces increased heart rate variability (HRV). This improvement in HRV shows a large effect and has a significant impact on reducing depression symptoms. Other research, such as the study conducted by Reiner (2008, DOI: 10.1007/s10484-007-9046-6), confirms that resonance breathing reduces state and trait anxiety in ambulatory patients when used regularly over several weeks. In addition, recent neuroimaging studies have demonstrated that prolonged breathing interventions induce morphological changes in the brain in healthy participants. Interestingly, the brain areas affected overlap with regions that show changes in patients with mental disorders (Sharma & Newberg, 2015, DOI: 10.2174/2210676605666150311223728). Away from these positive neurobiological effects, numerous experimental studies show that resonance breathing can activate homeostatic mechanisms. This occurs through modulation of the autonomic nervous system, including neuroendocrine responses, inflammatory activity, and cardiovascular function. Increased levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and C-reactive protein (CRP), which are associated with more severe clinical symptoms, have been observed in patients with psychosomatic disorders, such as depression or chronic pain disorders. At the same time, reduced vagal-mediated HRV was also observed in these patients. It is suspected that the reduction of vagal-mediated HRV via the so-called cholinergic anti-inflammatory pathway (Pavlov & Tracey, 2017, DOI: 10.1038/nn.4477) has an influence on systemic inflammation levels and could be a potential cause for the chronic increase in inflammation. For example, in our own study (BEAT-COVID), we demonstrated that inflammatory levels were significantly reduced the following day, respectively, after performing resonance breathing in hospitalized patients with COVID-19 (Balint et al. 2022, DOI: 10.3389/fimmu.2022.928979, DRKS00023971). The present VAST study aims to investigate the efficacy of a breathing intervention in patients at the University Hospital for Psychosomatic Medicine and Psychotherapy in Ulm, Germany. It is investigated whether resonance breathing before or during inpatient or day clinic therapy leads to an additional improvement of the emotion regulation ability in patients with depression, anxiety and somatoform disorders.

Health condition or problem studied

Free text:
Patients of the Department of Psychosomatic Medicine and Psychotherapy, excluding ICD10: F50.0 (anorexia nervosa) , F50.1 (atypical anorexia nervosa), F50.2 (bulimia nervosa), F50.3 (atypical bulimia nervosa), F60. (personality disorder) as main diagnosis, Z45.00 (implanted pacemaker), Z34 (pregnancy), Z39. (breast feeding), F45.33 (hyperventilation syndrome), E66. (obesity BMI>30)
Healthy volunteers:
No

Interventions, Observational Groups

Arm 1:
Intervention group (IG): Patients on the waiting list of the Department of Psychosomatic Medicine and Psychotherapy of the Ulm University Medical Center perform vagus nerve stimulating breathing technique at least 4 weeks BEFORE admission to inpatient and day clinic therapy. Breathing technique: daily 2x 10 min slow-paced breathing (4sec inhalation, 6sec exhalation; see DRKS00023971), supported by the app "Breath Ball" with automatic diary function.
Arm 2:
Care as Usual group (CAU): Patients on the waiting list of the Department of Psychosomatic Medicine and Psychotherapy of the Ulm University Medical Center are treated as CAU. FROM THE BEGINNING of a (partial) inpatient therapy, this group also receives the same vagus nerve-stimulating breathing technique for 2x10min daily for at least 4 weeks. Breathing technique: daily 2x 10 min slow-paced breathing (4sec inhalation, 6sec exhalation; see DRKS00023971), supported by the app "Breath Ball" with automatic diary function.

Endpoints

Primary outcome:
Emotion Regulation Questionnaire (EPS25)
Secondary outcome:
Quality of life (VAS), Somatoform complaints (PHQ-15), Depressiveness (PHQ-9), Generalised anxiety (GAD-7), Inflammation levels (IL-6, IL1b, TNF-a, hsCRP), Utilisation of care services (CSSRI)

Study Design

Purpose:
Treatment
Allocation:
Randomized controlled study
Control:
  • Control group receives no treatment
Phase:
N/A
Study type:
Interventional
Mechanism of allocation concealment:
In a sealed envelope, opening only after informed consent and inclusion into the study
Blinding:
No
Assignment:
Parallel
Sequence generation:
Stata command "randomize" Lock Morgan, K. and Rubin, D. B. (2012). Rerandomization to improve covariate balance in experiments. Ann. Statist. Volume 40, Number 2, 1263-1282.
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting ongoing
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Monocenter study
Recruitment location(s):
  • University medical center Universitätsklinikum Ulm, Klinik für Psychosomatische Medizin und Psychotherapie Ulm Ulm

Recruitment period and number of participants

Planned study start date:
2023-12-07
Actual study start date:
2023-12-07
Planned study completion date:
2024-10-01
Actual Study Completion Date:
No Entry
Target Sample Size:
60
Final Sample Size:
No Entry

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
60 Years
Additional Inclusion Criteria:
- Patients on the waiting list for inpatient or day clinic therapy at the Department of Psychosomatic Medicine and Psychotherapy Ulm - Sufficient level of German language

Exclusion Criteria

- Patients with eating disorders (anorexia or bulimia nervosa) - Patients with personality disorder as the primary diagnosis - Implanted cardiac pacemaker - Known hyperventilation syndrome - Pregnancy and breastfeeding - BMI >30 or BMI<18

Addresses

Primary Sponsor

Address:
Klinik für Psychosomatische Medizin und Psychotherapie Ulm
Dr. Marc N. Jarczok
Albert-Einstein-Allee 23
89081 Ulm
Germany
Telephone:
0049 (0) 73150061810
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.uniklinik-ulm.de/psychosomatische-medizin-und-psychotherapie.html
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Klinik für Psychosomatische Medizin und Psychotherapie
Dr. Marc N. Jarczok
Albert-Einstein-Allee 23
89081 Ulm
Germany
Telephone:
0049 (0) 73150061810
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.uniklinik-ulm.de/psychosomatische-medizin-und-psychotherapie.html

Contact for Public Queries

Address:
Klinik für Psychosomatische Medizin und Psychotherapie
Dr. Marc N. Jarczok
Albert-Einstein-Allee 23
89081 Ulm
Germany
Telephone:
0049 (0) 73150061810
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.uniklinik-ulm.de/psychosomatische-medizin-und-psychotherapie.html

Principal Investigator

Address:
Klinik für Psychosomatische Medizin und Psychotherapie
Dr. Marc N. Jarczok
Albert-Einstein-Allee 23
89081 Ulm
Germany
Telephone:
0049 (0) 73150061810
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.uniklinik-ulm.de/psychosomatische-medizin-und-psychotherapie.html

Sources of Monetary or Material Support

Institutional budget, no external funding (budget of sponsor/PI)

Address:
Klinik für Psychosomatische Medizin und Psychotherapie Ulm
Albert-Einstein-Allee 23
89081 Ulm
Germany
Telephone:
0049 (0) 73150061810
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.uniklinik-ulm.de/psychosomatische-medizin-und-psychotherapie.html

Ethics Committee

Address Ethics Committee

Address:
Ethikkommission der Universität Ulm
Oberberghof 7
89081 Ulm
Germany
Telephone:
+49-731-50022050
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.uni-ulm.de/einrichtungen/ethikkommission-der-universitaet-ulm/

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2023-01-18
Ethics committee number:
17/23
Vote of the Ethics Committee:
Approved
Date of the vote:
2023-04-26

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
Yes
IPD Sharing Plan:
Individual participant data available shared: yes What data: IPD collected for primary and secondary outcomes, after deidentification What other documents: study protocol, statistical analysis plan, informed consent form, clinical study report, analytical code Data available when: immediately after relevant scientific publication, no end date Data shared with: anyone who wishes to access the data, available via an DOI link For what types of analysis: CC BY-NC-SA 4.0 LEGAL CODE Attribution-NonCommercial-ShareAlike 4.0 International By what mechanism made available: Data available indefinitely at OPARU Universität Ulm https://oparu.uni-ulm.de/xmlui/

Study protocol and other study documents

Publication of study results

Planned publication:
Ende 2024
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry